Genomatica, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Genomatica. The number of shares to be offered and the price range for the offering have not yet been determined.
Genomatica CEO Christophe Schilling earned his Ph.D. in Bioengineering in 2000 at the UC San Diego Jacobs School of Engineering, under the guidance of professor Bernhard Palsson, the Galetti Professor of Bioengineering in the Department of Bioengineering.
Schilling launched Genomatica along with Palsson in 2000. Their aim was to enable the chemical industry, through Genomatica’s novel bio-manufacturing processes, to transform its feedstock base and take the “petro” out of the “petro-chemicals” business.Currently, professor Palsson serves at the chairman of the Genomatica scientific advisory board.